Our high-yield bioreactor design is specifically optimized for the unique process demands of mRNA vaccine manufacturing, delivering GMP-compliant, high-stability cultivation environments for E. coli fermentation, microbial strain proliferation, and plasmid DNA amplification. Tailored to maximize plasmid yield and maintain genetic stability, the engineered system eliminates process fluctuations and contamination risks, supporting reliable process development, scale-up validation, and commercial-grade mRNA vaccine raw material production.
Featuring process-intensified structural optimization, the bioreactor adopts customized high-efficiency oxygen transfer systems, uniform fluid mixing geometry, and precisely tuned shear force control. It enables stable high-density microbial growth and sustained plasmid replication through accurate closed-loop regulation of temperature, pH, dissolved oxygen, and feeding strategies. The yield-oriented design effectively boosts biomass accumulation and target plasmid output while reducing abnormal strain variation, laying a solid foundation for high-purity, high-efficiency downstream mRNA transcription and purification workflows.
Constructed with premium 316L biocompatible stainless steel, all product-contact surfaces feature mirror polishing, seamless welding and dead-space-free layout. The fully closed sterile production configuration supports automated CIP/SIP sterilization cycles,
completely avoiding exogenous contamination and residual impurities. Equipped with high-precision sensor suites and full-process data traceability functions, the bioreactor fully complies with cGMP, FDA and EMA regulatory standards, meeting strict validation and audit requirements for mRNA vaccine pharmaceutical production.
Built with modular and scalable architecture, our high-yield mRNA vaccine bioreactor supports flexible process iteration, strain switching and capacity expansion from lab-scale research to industrial mass production. With intelligent automated operation, low operational deviation and long-term stable performance, the design significantly shortens production cycles, reduces unit manufacturing costs, and provides a future-proof, high-efficiency core equipment solution for standardized and large-scale mRNA vaccine commercialization.
